Berberine protects against diabetic kidney disease via promoting PGC‐1α‐regulated mitochondrial energy homeostasis

Xin Qin,Ming Jiang,Yan Zhao,Jing Gong,Hao Su,Fen Yuan,Ke Fang,Xiaoyi Yuan,Xiao Yu,Hui Dong,Fuer Lu

DOI: https://doi.org/10.1111/bph.14935

IF: 7.3

2020-07-07

British Journal of Pharmacology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Lipid metabolism disorder and disturbed mitochondrial bioenergetics play pivotal roles in the occurrence and development of diabetic kidney disease (DKD). Berberine (BBR) is a kind of alkaloid derived from Chinese herbal medicine. It has multiple therapeutic actions on diabetes mellitus and its complications, including regulation of glucose and lipid metabolism, improvement of insulin sensitivity and alleviation of oxidative damage. Here we investigated the renoprotective effects of BBR.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Combined clinical study in DKD patients with experimental studies in diabetic mice and cultured podocytes, we characterized the energy metabolism profiles based on metabolomics, investigated molecular targets and mechanisms of BBR at regulating mitochondrial function and bioenergetics, and testified the effects of BBR on metabolic alterations in DKD animal model.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Metabolomics examination suggested altered mitochondrial fuel usage and generalized mitochondrial dysfunction in DKD patients. BBR intervention potently reversed metabolic disorders, podocyte damage and glomerulosclerosis in db/db mice. Lipid accumulation, excessive generation of mitochondrial reactive oxygen species, mitochondrial dysfunction and insufficient fatty acids oxidation in DKD mouse models and cultured podocytes were significantly suppressed by BBR. The protective mechanism of BBR might involve the activation of peroxisome proliferator‐activated receptor γ coactivator‐1α (PGC‐1α) signaling pathway, thereby promoting mitochondrial energy homeostasis and fatty acid oxidation in podocytes.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>Our research elucidated that PGC‐1α‐mediated mitochondrial bioenergetics might play a key role in lipid disorder‐induced podocyte damage and development of DKD. Restoration of PGC‐1α activity and the energy homeostasis by BBR might be a potential therapeutic strategy against DKD.</p></section>

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is lipid metabolism disorders and mitochondrial bioenergetic disorders in diabetic kidney disease (DKD). Specifically, the article explores whether berberine (BBR) can improve mitochondrial function and fatty acid oxidation in DKD patients by activating the peroxisome proliferator - activated receptor γ co - activator 1α (PGC - 1α) signaling pathway, thereby protecting the kidneys.

### Background and Purpose of the Paper

Diabetic kidney disease (DKD) is one of the most serious and common complications of diabetes, and there is currently no effective treatment method. Lipotoxicity is considered one of the main pathogenic mediators of DKD, which can cause oxidative stress damage and disrupt the energy homeostasis of the kidneys, leading to podocyte damage and glomerulosclerosis. Kidney cells have a high energy demand, which is mainly met by generating ATP through mitochondrial oxidative phosphorylation (OXPHOS). Among them, fatty acid oxidation (FAO) provides about 70% of the energy supply. However, mitochondrial dysfunction and FAO defects have been widely described in DKD patients.

### Research Questions

1. **Mitochondrial Dysfunction in DKD**: Are there changes in mitochondrial fuel use and extensive mitochondrial dysfunction in DKD patients?
2. **Therapeutic Effect of BBR**: Can BBR reverse metabolic disorders, podocyte damage and glomerulosclerosis in DKD patients?
3. **Molecular Mechanism**: Does BBR promote mitochondrial energy homeostasis and fatty acid oxidation by activating the PGC - 1α signaling pathway?

### Main Research Contents

1. **Combination of Clinical and Experimental Studies**: By combining clinical studies of DKD patients and experiments on diabetic mice and cultured podocytes, characterize the energy metabolism profile and investigate the molecular targets and mechanisms by which BBR regulates mitochondrial function and bioenergetics.
2. **Metabolomics Analysis**: By performing gas chromatography - mass spectrometry (GC/MS) analysis on plasma metabolites of DKD patients and healthy controls, reveal changes in mitochondrial fuel use and extensive mitochondrial dysfunction in DKD patients.
3. **Mechanism of Action of BBR**: Through various experimental methods (such as Western blotting, qRT - PCR, immunofluorescence staining, etc.), prove that BBR improves mitochondrial function and fatty acid oxidation, reduces lipid accumulation and metabolic disorders by activating the AMPK/PGC - 1α signaling pathway.

### Conclusions and Significance

Studies have shown that BBR may become a potential strategy for treating DKD by restoring PGC - 1α activity and energy homeostasis. This finding provides new hope for the treatment of DKD and reveals the crucial role of PGC - 1α - mediated mitochondrial bioenergetics in podocyte damage caused by lipid disorders and the development of DKD.

### Key Formulas and Terms

- **AMPK/PGC - 1α Signaling Pathway**: \[ \text{AMPK} \rightarrow \text{PGC - 1α} \]
- **Fatty Acid Oxidation (FAO)**: \[ \text{Fatty Acid} + O_2 \rightarrow CO_2 + H_2O + ATP \]
- **Oxidative Phosphorylation (OXPHOS)**: \[ \text{ADP} + P_i + O_2 \rightarrow ATP + H_2O \]

Through these studies, the authors reveal the potential of BBR in the treatment of DKD and provide an important basis for further exploring its specific mechanisms.